VivoSeq
Other

R/R AML

1

Pipeline Programs↗

8

Active Trials↗

6

Companies Involved↗

R/R AML is an early-stage landscape with 1 program across 6 companies. The most active players are Genmab, Oryzon Genomics S.A., Taiho Oncology, Inc..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Genmab logo

Genmab

1 program

Phase 1O

Oryzon Genomics S.A.

0 programs

PreclinicalTaiho Oncology, Inc. logo

Taiho Oncology, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalC

Carbiogene Therapeutics Co. Ltd.

0 programs

PreclinicalA

ARCE Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

GEN3018

Genmab

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Recruiting7 · 54%
Completed2 · 15%
Terminated1 · 8%
Not yet recruiting1 · 8%
Unknown status1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

Off-the-shelf CD123 CAR-NK for R/R AML
Recruiting·PPeking University People's Hospital·Phase 1·NCT06201247·12 enrolled
CAV Regimen for R/R AML
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05657639·68 enrolled
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Recruiting·OOryzon Genomics S.A.·Phase 1·NCT05546580·50 enrolled
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Recruiting·EETH Zurich·Phase 2·NCT06138990·88 enrolled
Tazemetostat and Palbociclib With CPX-351for R/R AML
Recruiting·TThomas Jefferson University·Phase 1·NCT05627232·24 enrolled
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Recruiting·AARCE Therapeutics, Inc.·Phase 1/2·NCT06680752·49 enrolled
An Open-Label, Multicenter, First-in-Human Trial of GEN3018 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Recruiting·Genmab logoGenmab·Phase 1·NCT07384715·78 enrolled
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Not yet recruiting·MMassachusetts General Hospital·Phase 1·NCT07355335·24 enrolled
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Completed·—·Phase 1·NCT04220684·19 enrolled
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
Completed·Pfizer logoPfizer·Phase 4·NCT03727750·51 enrolled
A Study of TAS1440 With ATRA in Subjects With r/r AML
Terminated·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT04282668·52 enrolled
DEC-C and Thioguanine for R/R AML
Withdrawn·—·Phase 2·NCT06351306
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
Unknown status·CCarbiogene Therapeutics Co. Ltd.·Phase 1·NCT04803929·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)